AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26678684 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 334
Study 26678860 — intervention group
Group type: EXPERIMENTAL
Intervention: SNOT-22 subdomains and LK variables
Number of subjects: 629
Study 26678860 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted combination of symptom domains and endoscopic attributes
Number of subjects: 629
Study 26679295 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD Online (unguided self-help intervention)
Number of subjects: 300
Study 26679295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lantern (guided self-help intervention)
Number of subjects: 300
Study 26679295 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 300
Study 26679295 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD Online and Lantern
Number of subjects: 300
Study 26679868 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*01 allele
Number of subjects: 10228
Study 26679868 — intervention group
Group type: EXPERIMENTAL
Intervention: BTNL2 blocking in T-cell stimulation assays
Number of subjects: 10228
Study 26680241 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned rehospitalizations (inpatient or observation status) within 30 days after discharge
Number of subjects: 12312
Study 26680241 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned rehospitalizations for cardiovascular reasons
Number of subjects: 12312
Study 26680241 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in hospital rates of 30-day unplanned rehospitalization
Number of subjects: 12312
Study 26680241 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with unplanned rehospitalization
Number of subjects: 12312
Study 26681111 — intervention group
Group type: EXPERIMENTAL
Intervention: HYD 20-120 mg daily
Number of subjects: 106
Study 26681124 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella RP device
Number of subjects: 30
Study 26681676 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day until progression or intolerance
Number of subjects: 134
Study 26681716 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C
Number of subjects: 217
Study 26681716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructosamine
Number of subjects: 217
Study 26681716 — intervention group
Group type: EXPERIMENTAL
Intervention: GA
Number of subjects: 217
Study 26681716 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C combined with Fructosamine
Number of subjects: 217
Study 26681716 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C combined with GA
Number of subjects: 217
Study 26681756 — intervention group
Group type: EXPERIMENTAL
Intervention: PZ-128 (0.01-2 mg/kg) administered by 1 to 2 hours continuous intravenous infusion
Number of subjects: 31
Study 26681756 — intervention group
Group type: EXPERIMENTAL
Intervention: PZ-128 (0.5 mg/kg) with aspirin
Number of subjects: 31
Study 26681756 — intervention group
Group type: EXPERIMENTAL
Intervention: PZ-128 (0.5 mg/kg)
Number of subjects: 31
Study 26681756 — intervention group
Group type: EXPERIMENTAL
Intervention: PZ-128
Number of subjects: 31
Study 26682038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual allergy immunotherapy tablet (GRAZAX®) plus standard treatment
Number of subjects: 50
Study 26682038 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard treatment
Number of subjects: 50
Study 26682232 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform users (active and curious)
Number of subjects: 633
Study 26682232 — intervention group
Group type: COMPARATOR
Intervention: Nonusers
Number of subjects: 633
Study 26684009 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb Everolimus-Eluting BVS (Abbott Vascular, Santa Clara, CA, USA)
Number of subjects: 0
Study 26684198 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and concomitant-adjuvant temozolomide chemotherapy
Number of subjects: 0
Study 26684198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning assessments, specific blood biomarkers measures, and magnetic resonance imagery
Number of subjects: 0
Study 26684198 — intervention group
Group type: EXPERIMENTAL
Intervention: New cognitive test
Number of subjects: 0
Study 26684274 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum UA levels (per SD increase)
Number of subjects: 5074
Study 26684274 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline UA levels
Number of subjects: 5074
Study 26684818 — intervention group
Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 819
Study 26684818 — intervention group
Group type: COMPARATOR
Intervention: ZDV
Number of subjects: 819
Study 26684868 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use disorder (AUD) participants
Number of subjects: 48
Study 26684868 — intervention group
Group type: COMPARATOR
Intervention: Substance use disorder (SUD) participants
Number of subjects: 48
Study 26684868 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AUD and SUD participants
Number of subjects: 48
Study 26684894 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived built environment variables in neighborhoods with higher residential density
Number of subjects: 1600
Study 26684894 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived neighborhood environment with friends or acquaintances similar in demographic characteristics
Number of subjects: 1600
Study 26684894 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed model regression analysis
Number of subjects: 1600
Study 26685073 — intervention group
Group type: EXPERIMENTAL
Intervention: Fontan operation
Number of subjects: 408
Study 26685704 — intervention group
Group type: COMPARATOR
Intervention: Control arm of the VIVIANE study
Number of subjects: 2838
Study 26685770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50 mg/kg
Number of subjects: 96
Study 26685770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 100 mg/kg
Number of subjects: 96
Study 26685936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovation® Prime stent graft under least invasive conditions using a fast-track protocol
Number of subjects: 250
Study 26685936 — intervention group
Group type: COMPARATOR
Intervention: Standard EVAR (not explicitly defined in the abstract)
Number of subjects: 250
Study 26686257 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited compression ultrasonography (group 2)
Number of subjects: 1162
Study 26686257 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended whole-leg compression ultrasonography (group 3)
Number of subjects: 1162
Study 26686257 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (DVT ruled out)
Number of subjects: 1162
Study 26686257 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (DVT ruled out)
Number of subjects: 1162
Study 26686257 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (DVT ruled out)
Number of subjects: 1162
Study 26686256 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide at a starting dose of 50 mg/day, increased by 50 mg/day increments every 4 weeks up to a maximum of 200 mg/day if no response was seen.
Number of subjects: 31
Study 26687320 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine-containing regimens
Number of subjects: 16304
Study 26687320 — intervention group
Group type: COMPARATOR
Intervention: Non-zidovudine antiretroviral regimens
Number of subjects: 16304
Study 26687423 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m² once a day for days 1-5 of each 28-day cycle and lenalidomide (initially 50 mg for 10 days, later adjusted to 25 mg for 5 days)
Number of subjects: 88
Study 26687423 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine and lenalidomide combination
Number of subjects: 88
Study 26687796 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 1 (2.5 mCi/m²)
Number of subjects: 17
Study 26687796 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 2 (5.0 mCi/m²)
Number of subjects: 17
Study 26687796 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 3 (7.5 mCi/m²)
Number of subjects: 17
Study 26687796 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 4 (10.0 mCi/m²)
Number of subjects: 17
Study 26687796 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-DOTA-epratuzumab radioimmunotherapy at all levels
Number of subjects: 17
Study 26687956 — intervention group
Group type: EXPERIMENTAL
Intervention: HbAS (sickle cell trait)
Number of subjects: 1543
Study 26687956 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD A-/A- homozygous girls
Number of subjects: 1543
Study 26687956 — intervention group
Group type: EXPERIMENTAL
Intervention: HbAC
Number of subjects: 1543
Study 26687956 — intervention group
Group type: EXPERIMENTAL
Intervention: HbAS
Number of subjects: 1543
Study 26687958 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin 12 mg/m(2) combined with CHOP (intravenous cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.4 mg/m(2) [maximum 2 mg], oral prednisone 40 mg/m(2))
Number of subjects: 37
Study 26687958 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin 10 mg/m(2) combined with CHOP
Number of subjects: 37
Study 26687958 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin 8 mg/m(2) combined with CHOP
Number of subjects: 37
Study 26687958 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin 12 mg/m(2) combined with CHOP
Number of subjects: 37
Study 26687958 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin combined with CHOP
Number of subjects: 37
Study 26688132 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 0
Study 26688485 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg oral three times a week and bortezomib 1.3 mg/m² intravenous two times a week for 2 of 3 weeks for up to eight cycles.
Number of subjects: 25
Study 26688485 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat and bortezomib combination treatment
Number of subjects: 25
Study 26688487 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04449913 at 80 mg
Number of subjects: 47
Study 26688487 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04449913 at 600 mg
Number of subjects: 47
Study 26688487 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04449913 (all doses)
Number of subjects: 47
Study 26688487 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04449913 at MTD (400 mg)
Number of subjects: 47
Study 26688487 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended phase 2 dose
Number of subjects: 47
Study 26688733 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 379
Study 26688733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 26688734 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-included diet (56 g providing 366 kcal per day)
Number of subjects: 112
Study 26688734 — intervention group
Group type: COMPARATOR
Intervention: Walnut-excluded diet
Number of subjects: 112
Study 26688787 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational plan for retigabine (retigabine Physician's Guide)
Number of subjects: 294
Study 26689767 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir, PegIFN, and RBV for 12 weeks
Number of subjects: 57
Study 26689767 — intervention group
Group type: COMPARATOR
Intervention: Historical controls treated with PegIFN and RBV for 24 weeks
Number of subjects: 57
Study 26690287 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus supplementation
Number of subjects: 63
Study 26690712 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI in MGUS patients
Number of subjects: 46
Study 26690712 — intervention group
Group type: EXPERIMENTAL
Intervention: CT in SMM patients
Number of subjects: 46
Study 26690712 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI in SMM patients
Number of subjects: 46
Study 26690712 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT in MM patients
Number of subjects: 46
Study 26690712 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI in MM patients
Number of subjects: 46
Study 26690712 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF-PET/CT in MM patients
Number of subjects: 46
Study 26690793 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polydioxanone stents
Number of subjects: 4
Study 26691513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative trans-fontanellar cerebral ultrasonography (TFCU)
Number of subjects: 35
Study 26691547 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and Sofosbuvir (400 mg) administered as one tablet once daily for 12 weeks
Number of subjects: 70
Study 26692015 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 regional, standardised, sports club based exercise sessions
Number of subjects: 60000
Study 26692015 — intervention group
Group type: COMPARATOR
Intervention: Informative written brochure
Number of subjects: 60000
Study 26692236 — intervention group
Group type: EXPERIMENTAL
Intervention: High Contact-Moderate Conflict-Moderate Support
Number of subjects: 240
Study 26692236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Contact-Moderate Conflict-Low Support
Number of subjects: 240
Study 26692236 — intervention group
Group type: EXPERIMENTAL
Intervention: High Conflict-Moderate Contact-Moderate Support
Number of subjects: 240
Study 26692236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Conflict-Moderate Contact-Moderate Support
Number of subjects: 240
Study 26692248 — intervention group
Group type: EXPERIMENTAL
Intervention: E-XLPE liner
Number of subjects: 977
Study 26692248 — intervention group
Group type: COMPARATOR
Intervention: AXL liner
Number of subjects: 977
Study 26692248 — intervention group
Group type: EXPERIMENTAL
Intervention: E-XLPE and AXL liners
Number of subjects: 977
Study 26692255 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (SRIs)
Number of subjects: 263
Study 26692255 — intervention group
Group type: COMPARATOR
Intervention: No SRI exposure (Control)
Number of subjects: 263
Study 26692255 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (SRIs) at delivery
Number of subjects: 263
Study 26692255 — intervention group
Group type: COMPARATOR
Intervention: No SRI exposure at delivery (Control)
Number of subjects: 263
Study 26692553 — intervention group
Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 9203
Study 26692553 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight
Number of subjects: 9203
Study 26692553 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 9203
Study 26692553 — intervention group
Group type: EXPERIMENTAL
Intervention: BSA
Number of subjects: 9203
Study 26693033 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 548
Study 26693033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study 26693034 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 10 mg/d
Number of subjects: 70
Study 26693034 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 20 mg/d
Number of subjects: 70
Study 26693034 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/d
Number of subjects: 70
Study 26693034 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone (all doses)
Number of subjects: 70
Study 26693035 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation (EECP) therapy, 260 mm Hg pressure, 60 minutes, 5 days a week for 7 weeks (35 sessions)
Number of subjects: 50
Study 26693035 — intervention group
Group type: EXPERIMENTAL
Intervention: EECP therapy
Number of subjects: 50
Study 26693967 — intervention group
Group type: EXPERIMENTAL
Intervention: Promillekoll app (real-time estimated eBAC calculation)
Number of subjects: 0
Study 26693967 — intervention group
Group type: EXPERIMENTAL
Intervention: PartyPlanner app (real-time eBAC calculation with planning and follow-up functions)
Number of subjects: 0
Study 26693967 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleCoach app (skills training)
Number of subjects: 0
Study 26693967 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 26693967 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 0
Study 26694975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300-450 mg/day)
Number of subjects: 5
Study 26694975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 26695065 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadofosveset trisodium injection using a dual-injection protocol (70% bolus / 30% slow infusion)
Number of subjects: 14
Study 26695065 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadofosveset trisodium injection using a dual-injection protocol (60% bolus / 40% slow infusion)
Number of subjects: 14
Study 26695065 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadofosveset injection optimized for lowest intravascular T1 time
Number of subjects: 14
Study 26695349 — intervention group
Group type: EXPERIMENTAL
Intervention: MSN (extended-release morphine sulfate with sequestered naltrexone hydrochloride)
Number of subjects: 1012
Study 26695837 — intervention group
Group type: EXPERIMENTAL
Intervention: PAs in charge (100% PA)
Number of subjects: 179
Study 26695837 — intervention group
Group type: COMPARATOR
Intervention: MDs in charge (100% MD)
Number of subjects: 179
Study 26695837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed PA/MR model
Number of subjects: 179
Study 26695837 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical specialists in charge (100% MS)
Number of subjects: 179
Study 26695837 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical residents in charge (100% MR)
Number of subjects: 179
Study 26695935 — intervention group
Group type: EXPERIMENTAL
Intervention: CART based on five variables (baseline dyspnea, cardiac disease, paradoxical breathing or use of accessory inspiratory muscles, age, Glasgow Coma Scale score)
Number of subjects: 2487
Study 26695935 — intervention group
Group type: EXPERIMENTAL
Intervention: CART improved by adding the Charlson Comorbidity Index
Number of subjects: 2487
Study 26695935 — intervention group
Group type: EXPERIMENTAL
Intervention: CART based on five variables
Number of subjects: 2487
Study 26695935 — intervention group
Group type: EXPERIMENTAL
Intervention: CART
Number of subjects: 2487
Study 26696388 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women with reduced ovarian reserve (undetectable AMH)
Number of subjects: 74
Study 26696388 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal women with measurable AMH
Number of subjects: 74
Study 26696455 — intervention group
Group type: EXPERIMENTAL
Intervention: DANUBIO balloon inflation after Nile PAX stent placement
Number of subjects: 52
Study 26696749 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat treatment
Number of subjects: 0
Study 26696953 — intervention group
Group type: EXPERIMENTAL
Intervention: SUDEP Risk Inventory (SUDEP-7)
Number of subjects: 25
Study 26696953 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV)
Number of subjects: 25
Study 26697218 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook-delivered lifestyle counselling and monitoring of physical activity (Fb + Act, n = 15)
Number of subjects: 46
Study 26697218 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook-delivered lifestyle counselling without self-monitoring (Fb, n = 16)
Number of subjects: 46
Study 26697218 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 46
Study 26698225 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational study
Number of subjects: 5000
Study 26698306 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath VOC mass ion biomarkers
Number of subjects: 70
Study 26698306 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath VOC mass ion biomarkers at Laboratory A
Number of subjects: 70
Study 26698306 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath VOC mass ion biomarkers at Laboratory B
Number of subjects: 70
Study 26698306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of breath biomarkers with chest CT
Number of subjects: 70
Study 26698309 — intervention group
Group type: EXPERIMENTAL
Intervention: Adho Mukha Svanasana
Number of subjects: 20
Study 26698309 — intervention group
Group type: EXPERIMENTAL
Intervention: Uttanasana
Number of subjects: 20
Study 26698309 — intervention group
Group type: EXPERIMENTAL
Intervention: Halasana
Number of subjects: 20
Study 26698309 — intervention group
Group type: EXPERIMENTAL
Intervention: Viparita Karani
Number of subjects: 20
Study 26698868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) at doses of up to 300 mg/m(2) over 4 hours
Number of subjects: 48
Study 26698868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI) of nab-paclitaxel over 1 hour
Number of subjects: 48
Study 26698868 — intervention group
Group type: COMPARATOR
Intervention: Hepatic arterial infusion (HAI) of nab-paclitaxel
Number of subjects: 48
Study 26698910 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 1
Study 26698910 — intervention group
Group type: COMPARATOR
Intervention: Lorlatinib
Number of subjects: 1
Study 26699604 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation using the Symplicity Spyral multielectrode renal denervation catheter
Number of subjects: 0
Study 26699604 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study 26699672 — intervention group
Group type: EXPERIMENTAL
Intervention: P-Vrs curve
Number of subjects: 22
Study 26699672 — intervention group
Group type: EXPERIMENTAL
Intervention: EELV-Cst,rs
Number of subjects: 22
Study 26699672 — intervention group
Group type: EXPERIMENTAL
Intervention: CT (not inflated)
Number of subjects: 22
Study 26699672 — intervention group
Group type: EXPERIMENTAL
Intervention: CT (not + poorly inflated)
Number of subjects: 22
Study 26699701 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine Galactomannan-to-Creatinine Ratio
Number of subjects: 71
Study 26700120 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational tool (Preparatory Education About Clinical Trials)
Number of subjects: 1211
Study 26700485 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH-suppressive LT4 doses
Number of subjects: 122